Leadership

Alan S. Rudolph has had an active career in translating interdisciplinary life sciences into useful applications for biotechnology development and commercialization. His experience spans basic research to advanced development in academia, government laboratories, and in the nonprofit and private sectors. His scientific training translated into positions of leadership in each of these sectors with management of over $4B in investments in life sciences and biotechnology. Working for the Defense Department at the US Navy and the Defense Advanced Research Projects Agency, he led major programs in blood products, bioinspired engineering and neurotechnology. As founder and CEO, he led companies in medical countermeasures including cell therapeutics at Cellphire and protein diagnostics at Adlyfe and raised both non-dilutive and venture sources of capital in support. Dr. Rudolph also served as Vice President of Research at Colorado State University where he led a major expansion of research revenues and impacts. He has published more than 100 technical publications, three books, and has a number of issued patents from his work. He has a doctorate degree in zoology from the University of California at Davis and an MBA from George Washington University.

Dr. Goodrich received his B.S. degree in Chemistry from The Ohio State University and a Ph.D. in Biophysical Chemistry from the California Institute of Technology in Pasadena, California.  He currently serves as the Executive Director of the Infectious Disease Research Center (IDRC) at Colorado State University and holds a faculty position as Professor in the Department of Microbiology, Immunology and Pathology.  Dr. Goodrich has responsibility for oversight of the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), Regional Biocontainment Laboratory (RBL), and the Research Innovation Center (RIC) at Colorado State University.

Dr. Goodrich’s research has focused on the study of blood preservation, prevention of transfusion transmitted infections, and the development of methods for production of vaccine products. Dr. Goodrich formerly served as Vice President of Scientific and Clinical Affairs and Chief Scientific Officer, Blood Bank Technologies, for Terumo BCT, a leading global medical device manufacturer based in the United States. His responsibilities included oversight of research and development programs in the field of blood product processing and blood safety. He has worked in medical research for over 30 years.  He has been awarded over 58 patents covering technology in these areas and has co-authored over 200 peer reviewed articles and abstracts. He has also served as the Principal Investigator for grants totaling over $200M from the United States Department of Defense (Congressionally Designated Medical Research Program), BARDA, and the National Institutes of Health.

He is an active member of several professional organizations, including the American Chemical Society and the Association for the Advancement of Blood & Biotherapies. He is currently a member of the AABB committee on Public Policy and Strategy and a member of the Advisory Committee on Blood and Tissue Safety and Availability for the US Department of Health and Human Services.  Dr. Goodrich has also held a position as an Adjunct Professor of Chemistry at The Ohio State University since 2005.

In addition to being a co-founder of PhotonPharma and co-inventor of the technology, Dr. Goodrich was also a co-founder of CryoPharm Corporation, a startup company from Caltech, which sold technologies to COBE BCT in 1993 and Baxter International in 1996.  He is also a co-founder of Navigant Biotechnologies which was started out of the BCT organization in 2000 and folded into the Terumo BCT as part of a $2.63B acquisition by Terumo Corporation in 2011. Dr. Goodrich was a primary inventor of the technology platforms for these groups, which have raised over $300M in external investments and generated cumulative technology sales of close to $1B since market introductions.  He is also a recipient of the Order of Military Medical Merit (Honorary, O2M3) for his work in developing products to meet the needs of military personnel.

Dr. Ray is the founder of i3MedTech, a medical technology consulting firm.  She began her career as an engineer in the medical device industry in 1995, eventually working into technical leadership positions and senior executive roles.   She brings a breadth of experiences domestically and internationally, including automotive work at Audi AG in Ingolstadt Germany (in German), apheresis systems while at Gambro BCT (now Terumo BCT), fluid metering, handling, product design, and high-volume manufacturing automation while at Baxa Corporation both in Colorado (now Baxter Healthcare) and in Freilassing, Germany, while working with Kiefel GMBH, in vitro diagnostics and microfluidics while at MBio Diagnostics (now LightDeck Diagnostics), and in xenographic tissues and transfemoral aortic heart valves while at Colorado Medical.    

Dr. Ray received her Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in Bioengineering from the University of Colorado, her Master's in Business Administration from the University of Denver and her Doctorate in Business Administration from the Drexel University.

Bio to come.

Dr. Opgenorth has more than 30 years of experience in biopharma; 20 with Abbott Laboratories' Pharmaceutical division (now AbbVie) as a bench scientist and then as an executive creating and leading drug discovery teams that advanced 12 drugs into clinical development, including AbbVie's HCV drugs ViekiraPak and Mavyret. He was the primary internal champion for Abbott-biotech partnerships - Metabolex, Millennium Pharmaceuticals, KaroBio AB (now Karo Pharma), and Enanta Pharmaceuticals. Since Abbott, Terry served as the CEO of Vidasym, securing innovative R&D partnerships that allowed it to operate without venture funding. During his time there, Vidasym completed a human proof of concept study of VS-505 in Australia and a successful IND filing in the U.S. for VS-105. He is also the co-founder/CSO of VetDC, a veterinary oncology company that developed and launched the first FDA-CVM approved drug, Tanovea, for treatment of canine lymphoma and most recently served as the Executive Director for CSU Ventures' LAUNCHPAD, a program to support startup companies based on licensed technology from Colorado State University. Terry also serves as an independent director for VetDC, ForCast Orthopedics, and KromaTiD. He holds a B.A. in Liberal Arts (biology) from Calvin University, and M.S. and Ph.D degrees in Physiology from University of Illinois-Urbana.

Dr. Goodrich received his B.S. degree in Chemistry from The Ohio State University and a Ph.D. in Biophysical Chemistry from the California Institute of Technology in Pasadena, California.  He currently serves as the Executive Director of the Infectious Disease Research Center (IDRC) at Colorado State University and holds a faculty position as Professor in the Department of Microbiology, Immunology and Pathology.  Dr. Goodrich has responsibility for oversight of the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), Regional Biocontainment Laboratory (RBL), and the Research Innovation Center (RIC) at Colorado State University.

Dr. Goodrich’s research has focused on the study of blood preservation, prevention of transfusion transmitted infections, and the development of methods for production of vaccine products. Dr. Goodrich formerly served as Vice President of Scientific and Clinical Affairs and Chief Scientific Officer, Blood Bank Technologies, for Terumo BCT, a leading global medical device manufacturer based in the United States. His responsibilities included oversight of research and development programs in the field of blood product processing and blood safety. He has worked in medical research for over 30 years.  He has been awarded over 58 patents covering technology in these areas and has co-authored over 200 peer reviewed articles and abstracts. He has also served as the Principal Investigator for grants totaling over $200M from the United States Department of Defense (Congressionally Designated Medical Research Program), BARDA, and the National Institutes of Health.

He is an active member of several professional organizations, including the American Chemical Society and the Association for the Advancement of Blood & Biotherapies. He is currently a member of the AABB committee on Public Policy and Strategy and a member of the Advisory Committee on Blood and Tissue Safety and Availability for the US Department of Health and Human Services.  Dr. Goodrich has also held a position as an Adjunct Professor of Chemistry at The Ohio State University since 2005.

In addition to being a co-founder of PhotonPharma and co-inventor of the technology, Dr. Goodrich was also a co-founder of CryoPharm Corporation, a startup company from Caltech, which sold technologies to COBE BCT in 1993 and Baxter International in 1996.  He is also a co-founder of Navigant Biotechnologies which was started out of the BCT organization in 2000 and folded into the Terumo BCT as part of a $2.63B acquisition by Terumo Corporation in 2011. Dr. Goodrich was a primary inventor of the technology platforms for these groups, which have raised over $300M in external investments and generated cumulative technology sales of close to $1B since market introductions.  He is also a recipient of the Order of Military Medical Merit (Honorary, O2M3) for his work in developing products to meet the needs of military personnel.

Alan S. Rudolph has had an active career in translating interdisciplinary life sciences into useful applications for biotechnology development and commercialization. His experience spans basic research to advanced development in academia, government laboratories, and in the nonprofit and private sectors. His scientific training translated into positions of leadership in each of these sectors with management of over $4B in investments in life sciences and biotechnology. Working for the Defense Department at the US Navy and the Defense Advanced Research Projects Agency, he led major programs in blood products, bioinspired engineering and neurotechnology. As founder and CEO, he led companies in medical countermeasures including cell therapeutics at Cellphire and protein diagnostics at Adlyfe and raised both non-dilutive and venture sources of capital in support. Dr. Rudolph also served as Vice President of Research at Colorado State University where he led a major expansion of research revenues and impacts. He has published more than 100 technical publications, three books, and has a number of issued patents from his work. He has a doctorate degree in zoology from the University of California at Davis and an MBA from George Washington University.

Gary B. Gordon, M.D., Ph.D., is an accomplished pharmaceutical executive and strategic business leader with extensive experience in the development of drugs from first in-human studies to approval and commercialization. He brings innovative approaches to the process, leveraging advantageous regulatory pathways and close collaborations with investigators, patient advocacy groups and key academic and government consortiums.

Recently, Dr. Gordon served as the Vice President, Oncology Department at AbbVie (a spin-off of Abbott), where he oversaw the development of AbbVie’s oncology projects. He drove drug development innovations, expanded the staff, and advanced the Oncology pipeline. He played a critical role in the oncology business expansion, leading to Abbvie’s current position in Oncology. This includes the approval of venetoclax, several major acquisitions and other collaborations. Gary was on the Abbvie-Genentech team that received the 2017 Prix Galien award for the Best Pharmaceutical Product.

Dr. Gordon joined Abbott in 2003 as Global Project Head, rapidly advancing to the role of Divisional Vice President, Global Oncology Development.

Prior to AbbVie, Gary was Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals from 2001 to 2003. In this role, he helped obtain funding and five on market products. 

He entered the pharmaceutical industry in 1995, joining the G.D. Searle division of Monsanto, which eventually became part of Pharmacia. Dr. Gordon’s responsibilities included programs related to COX-2 inhibitors for the prevention and treatment of cancer, the development of angiogenesis inhibitors, and involvement in the hematopoietic and cancer immunization programs. He also helped establish a tissue bank and an Industry Academic interface program. He also co-chaired an AACR task force focused on the treatment and prevention of intraepithelial neoplasias.

Dr. Dow is a Professor in the Department of Clinical Sciences at Colorado State University and the director of the Center for Immune and Regenerative Medicine and he is also a member of the Flint Animal Cancer Center. He is also a board-certified internist and a member of the CSU Veterinary Teaching Hospital (VTH) small animal internal medicine group. His work focuses on development of new immunotherapeutic approaches to treatment of cancer and treatment and prevention of viral and bacterial diseases. A second program in his laboratory seeks to develop new cellular therapy approaches to treatment of drug-resistant bacterial infections. The studies he directs are highly focused on translational medicine, using rodent models combined with clinical studies in companion animals (dogs, cats, horses) to evaluate new cancer and anti-viral immunotherapies, with the goal of advancing to human clinical trials. His laboratory collaborates widely with investigators in the College of Veterinary Medicine and with colleagues at the medical school at the Anschutz Medical Center in Aurora, Colorado.